


Pharmacokinetics and Molecular Docking studies of Plant-Derived Natural Compounds to Exploring Potential Anti-Alzheimer Activity

Aftab Alam^{†1}, Naaila Tamkeen^{†1}, Nikhat Imam², Anam Farooqui¹, Mohd Murshad Ahmed¹, Shahnawaz Ali¹, Md Zubbair Malik¹ and Romana Ishrat^{1*}

¹Centre for Interdisciplinary Research in Basic Science, Jamia Millia Islamia, New Delhi, India- 110025

²Institute of Computer Science and Information Technology, Magadh University, Bodhgaya.



†= AA and NT contributed equally to this work.

*Corresponding Author:

Dr. Romana Ishrat

Assistant Professor
Computational & Bioinformatics lab
Centre for Interdisciplinary Research in Basic Science
Jamia Millia Islamia
New Delhi-110025, India
E-mail: rishrat@jmi.ac.in

Abstract

Alzheimer's disease (AD) is the leading cause of dementia, accounts for 60 to 80 percent cases. Two main factors called β -amyloid ($A\beta$) plaques and tangles are prime suspects in damaging and killing nerve cells. However, oxidative stress, the process which produces free radicals in cells, is believed to promote its progression to the extent that it may responsible for the cognitive and functional decline observed in AD. As of today there are few FDA approved drugs in the market for treatment, but their cholinergic adverse effect, potentially distressing toxicity and limited targets in AD pathology limits their use. Therefore, it is crucial to find an effective compounds to combat AD. We choose 45 plant-derived natural compounds that have antioxidant properties to slow down disease progression by quenching free radicals or promoting endogenous antioxidant capacity. However, we performed molecular docking studies to investigate the binding interactions between natural compounds and 13 various anti-Alzheimer drug targets. Three known Cholinesterase inhibitors (Donepezil, Galantamine and Rivastigmine) were taken as reference drugs over natural compounds for comparison and drug-likeness studies. Few of these compounds showed good inhibitory activity besides anti-oxidant activity. Most of these compounds followed pharmacokinetics properties that make them potentially promising drug candidates for the treatment of Alzheimer's disease.

Keywords: AD; Cholinesterase inhibitors; ROS; ADMET; Docking; Pharmacology; Pharmacokinetics

Graphical Abstract : Pharmacokinetics and Molecular docking studies of 45 natural antioxidant compounds with most known Alzheimer associated targets.

Introduction

Alzheimer's disease is one of the most common neurodegenerative disorders that normally cause dementia and affect the middle to old-aged persons, around one in four individuals over the age of 85[1]. Alzheimer's is a progressive disease, where dementia steadily gets worse over the years. The World Alzheimer Report 2015 led by King's College London found that there are currently around 46.8 million people living with dementia around the world, with numbers projected to nearly double every 20 years, increasing to 74.7 million by 2030 and 131.5 million by 2050 (Fig. 1). At the country level, ten countries are home to over a million people with dementia in 2015: China (9.5 million), US (4.2 million), India (4.1 million), Japan (3.1 million), Brazil (1.6 million), Germany (1.6 million), Russia (1.3 million), Italy (1.2 million), Indonesia (1.2 million) and France (1.2 million). Thus, this condition will bring gigantic financial and personal burdens to current and future generations. In order to deal with this problem, effective therapeutic and preventive interventions should be developed urgently.

Figure 1 People living with dementia around the World: 9.4 million people of Americas, 4.0 million of African region, 10.5 million of European countries and 22.9 million people of Asia are living with dementia in 2015. This no. will reach 15.8 and 29.9 million in Americas, 7.0 and 15.8 million in Africa, 13.4 and 18.6 million in Europe and 38.5 and 67.2 million in Asia in 2030 and 2050 respectively. (World Alzheimer Report)

There are no such drugs/treatments available that can cure AD or any other common type of dementia completely. However, medications have been developed for Alzheimer's disease that can temporarily attenuate the symptoms, or delay its progression. The U.S. Food and Drug Administration (FDA) have approved two medications-cholinesterase inhibitors and Memantine. Over the past decade, much of the research on Alzheimer disease (AD) has focused on oxidative stress mechanisms and its importance in disease pathogenesis. The net effect of oxygen radicals is damaging, such damage present in AD includes advanced glycation end products [2], nitration [3], lipid peroxidation adduction products [4-5] as well as carbonyl-modified neurofilament protein and free carbonyls [6-7]. Significantly, this damage involves all neurons at risk to death in AD, not just those containing neurofibrillary tangles.

Nature has gifted us lots of natural remedies in the form of fruits, leaves, bark, vegetables and nuts, etc. The various ranges of bioactive nutrients present in these natural products play a vital role in prevention and cure of various neurodegenerative diseases, such as AD, Parkinson's disease and other neuronal dysfunctions. Previous studies suggested that the naturally occurring phytochemicals, such as polyphenolic antioxidants found in fruits, vegetables, herbs and nuts, may potentially hinder neurodegeneration, and improve memory and cognitive functions.

In our study, we chose 45 natural compounds (antioxidant properties) of various plants from different databases ([Table 1](#)) for molecular docking and pharmacokinetics studies. Recent studies have demonstrated that the natural compounds and their derivatives possess wide range of biological activities like anti-tubercular, antifungal, antibacterial anti-malarial, anti-inflammatory and antioxidant activities [8-10].

Table 1: List of studied compounds and sources

S. no.	Compound	Molecular Formula	Plants and food sources
1.	Vitamin C	C ₆ H ₈ O ₆	Kakadu plum, Camu Camu, Acerola, citrus fruits (such as oranges, sweet lime, etc.), green peppers, broccoli, green leafy vegetables, black currants, strawberries, blueberries, seabuckthorn, raw cabbage and tomatoes.
2.	Vitamin E	C ₂₉ H ₅₀ O ₂	Wheat germ , seabuckthorn , nuts , seeds , whole grains , green leafy vegetables , kiwifruit , vegetable oil and fish-liver oil
3.	Coenzyme Q10	C ₅₉ H ₉₀ O ₄	Sardine, Mackrel, beef , pork , chicken heart , chicken liver , rapeseed oil, soybean oil, sesame oil, peanuts, parsley , perilla , broccoli , grapes , cauliflower , avocados etc
4.	Iodide	I ⁻	Sea vegetables, cranberries, yogurt, navy beans, strawberries, raw cheese, potatoes etc.
5.	Melatonin	C ₁₃ H ₁₆ N ₂ O ₂	Cherries, bananas, grapes, rice, cereals, herbs, plums, olive oil, wine, beer, pineapple, oranges etc.
6.	Alpha carotene	C ₄₀ H ₅₆	Carrots, sweet potatoes, pumpkin, winter squash, broccoli, green beans, green peas, spinach, turnip greens, collards, leaf lettuce, avocado, parsley etc.
7.	Astaxanthin	C ₄₀ H ₅₂ O ₄	Microalgae , yeast , Salmon , Trout , Krill , Shrimp , Crayfish , crustaceans etc.
8.	Beta carotene	C ₄₀ H ₅₆	Butternut squash, carrots, orange bell peppers, pumpkins, kale, peaches, apricots, mango, turnip greens, broccoli, spinach, and sweet potatoes.
9.	Canthaxanthin	C ₄₀ H ₅₂ O ₂	Pacific salmon, green algae, crustacean and fishes like Crap, Golden mullet, Seabream and Trush wasse.
10.	Lutein	C ₄₀ H ₅₆ O ₂	Spinach, kale, Swiss chard, collard greens, beet and mustard greens, endive, red pepper and okra.
11.	Lycopene	C ₄₀ H ₅₆	Cooked red tomato products like canned tomatoes, tomato sauce, tomato juice and garden cocktails, guava, red carrots , watermelons , gac , papayas etc.
12.	Zeaxanthin	C ₄₀ H ₅₆ O ₂	Paprika , corn , saffron , wolfberries , Spirulina , dark green leafy vegetables , such as kale , spinach , turnip greens , collard greens , romaine lettuce , watercress , Swiss chard and mustard greens.
13.	Apigenin	C ₁₅ H ₁₀ O ₅	Parsley , celery , celeriac , chamomile tea, flowers of chamomile plants, Navy bean etc
14.	Luteolin	C ₁₅ H ₁₀ O ₆	<i>Salvia tomentosa</i> , celery , broccoli , green pepper , parsley , thyme , dandelion, perilla , chamomile tea, carrots, olive oil, peppermint, rosemary, navel oranges, oregano, seeds of the palm <i>Aiphanes aculeate</i> etc.
15.	Tangeritin	C ₂₀ H ₂₀ O ₇	Tangerine and other citrus peels.
16.	Isorhamnetin	C ₁₆ H ₁₂ O ₇	Pungent yellow or red onions, Mexican tarragon (<i>Tagetes lucida</i>) etc.
17.	Kaempferol	C ₁₅ H ₁₀ O ₆	Apples, grapes, tomatoes, green tea, potatoes, onions, broccoli, Brussels sprouts, squash, cucumbers, lettuce, green beans, peaches, blackberries, raspberries, and spinach. Plants that are known to contain kaempferol include Aloe vera , Coccinia grandis , Cuscuta chinensis , Euphorbia pekinensis , Glycine max , Hypericum perforatum , Moringa oleifera , Rosmarinus officinalis , Sambucus nigra , and Toona sinensis .
18.	Myricetin	C ₁₅ H ₁₀ O ₈	Vegetables, fruits, nuts, berries, tea, and is also found in red wine.
19.	Quercetin	C ₁₅ H ₁₀ O ₇	Capers, lovage, dock like sorrel, radish leaves, carob fiber, dill, cilantro, Hungarian wax peppers, funnel leaves, onion (red), radicchio, watercress, buckwheat, kale etc.
20.	Eriodictyol	C ₁₅ H ₁₂ O ₆	In twigs of Millettia duchesnei , in Eupatorium armottianum , and its glycosides (eriodictin) in lemons and rose hips (<i>Rosa canina</i>).
21.	Hesperetin	C ₁₆ H ₁₄ O ₆	Lemons and sweet oranges.
22.	Naringenin	C ₁₅ H ₁₂ O ₅	Grapefruit, oranges, tomatoes (skin) and in water mint .

23.	Catechin	C ₁₅ H ₁₄ O ₆	Uncaria rhynchophylla , pome fruits, cocoa, prune juice, broad bean pod, acai oil, argan oil, peaches, green tea, vinegar, barley grain, etc
24.	Gallocatechin	C ₁₅ H ₁₄ O ₇	Green tea, bananas, persimmons and pomegranates.
25.	Epicatechin		Uncaria rhynchophylla , cacao beans, green tea etc.
26.	Epigallocatechin		St John's wort etc.
27.	Theaflavin	C ₂₉ H ₂₄ O ₁₂	Black tea etc.
28.	Daidzein	C ₁₅ H ₁₀ O ₄	Kwao Krua (Pueraria mirifica), Kudzu (Pueraria lobata), Maackia amurensis cell cultures, soybeans , lupin, fava beans, psoralea, Flemingia vestita , F. marophylla and coffee.
29.	Ganistein	C ₁₅ H ₁₀ O ₅	Lupin , fava beans , soybeans , kudzu , Flemingia vestita , F. macrophylla , coffee , Maackia amurensis cell cultures etc.
30.	Glycitein	C ₁₆ H ₁₂ O ₅	Soy food products.
31.	Resveratrol	C ₁₄ H ₁₂ O ₃	Skin of grapes , blueberries , raspberries , mulberries , lingonberry , senna and concentrated in red wine.
32.	Pterostilbene	C ₁₆ H ₁₆ O ₃	Almonds , various Vaccinium berries, grape leaves, vines and blueberries .
33.	Cyanidin	C ₁₅ H ₁₁ O ₆ ⁺	Grapes , bilberry , blackberry , blueberry , cherry , cranberry , elderberry , hawthorn , loganberry , açai berry, raspberry , apples , plums , red cabbage and red onion .
34.	Delphinidin	C ₁₅ H ₁₁ O ₇ ⁺	Cranberries , Concord grapes , pomegranates , bilberries etc
35.	Malvidin	C ₁₇ H ₁₅ O ₇ ⁺	Primula plants, blue pimpernel (Anagallis monelli), red wine, Vitis vinifera , chokeberries (Aronia sp), saskatoon berries (Amelanchier alnifolia) etc.
36.	Pelargonidin	C ₁₅ H ₁₁ O ₅ ⁺	Red geraniums (Geraniaceae), Philodendron (Araceae), flowers of blue pimpernel (Anagallis monelli , Myrsinaceae), raspberries , strawberries , blueberries , blackberries , cranberries , saskatoon berries , chokeberries , plums pomegranates , kidney beans etc.
37.	Peonidin	C ₁₆ H ₁₃ O ₆ ⁺	Raw cranberries, blueberries, plums, grapes, cherries, purple fleshed sweet potatoes, raw black rice and black bananas.
38.	Petunidin	C ₁₆ H ₁₃ O ₇ ⁺ (Cl ⁻)	Chokeberries (Aronia sp), Saskatoon berries (Amelanchier alnifolia) or different species of grape (for instance Vitis vinifera , or muscadine , Vitis rotundifolia), Indigo Rose tomatoes.
39.	Cichoric acid	C ₂₂ H ₁₈ O ₁₂	Cichorium intybus (chicory), E. purpurea , dandelion leaves, basil , lemon balm , and aquatic plants , including algae and seagrasses .
40.	Chlorogenic acid	C ₁₆ H ₁₈ O ₉	Leaves of Hibiscus sabdariffa , potatoes, flesh of eggplants , peach, prunes, green coffee bean extract and green tea.
41.	Cinnamic acid	C ₉ H ₈ O ₂	Oil of cinnamon, balsams such as storax, shea butter, seeds of plants such as brown rice, whole wheat, oats, coffee, apple, artichoke, peanut, orange and pineapple.
42.	Ellagic acid	C ₁₄ H ₆ O ₈	North American white oak (Quercus alba , European red oak (Quercus robur). Myriophyllum spicatum , medicinal mushroom Phellinus linteus , walnuts , pecans , cranberries , raspberries , strawberries , and grapes , as well as distilled beverages , peach and other plant foods .
43.	Gallic acid	C ₇ H ₆ O ₅	Parasitic plant Cynomorium coccineum , the aquatic plant Myriophyllum spicatum , the blue-green alga Microcystis aeruginosa . oak species, Caesalpinia mimosoides , and in the stem bark of Boswellia dalzielii , fruits (including strawberries, grapes, bananas), as well as teas , cloves and vinegars .
44.	Rosmarinic acid	C ₁₈ H ₁₆ O ₈	Ocimum basilicum (basil), Ocimum tenuiflorum (holy basil), Melissa officinalis (lemon balm), Rosmarinus officinalis (rosemary), Origanum majorana (marjoram), Salvia officinalis (sage), thyme and peppermint , (Prunella vulgaris) Heliotropium foertherianum Maranta (Maranta leuconeura , Maranta depressa) and Thalia (Thalia geniculata).
45.	Salicyclic acid	C ₇ H ₆ O ₃	Blackberries , blueberries , cantaloupes , dates , grapes , kiwi fruits , guavas , apricots , green pepper , olives , tomatoes , radish , chicory and mushrooms . Some herbs and spices contain high amounts, Of the legumes , seeds , nuts and cereals , only almonds , water chestnuts and peanuts have significant amounts.

In our study, all the 45 compounds have antioxidant properties and it has been shown that treatment with these compounds certainly contribute to their neuroprotective effects and it is a potential approach for slowing disease progression. Therefore, we further screened our compounds against Alzheimer, which is caused by oxidative stress and it is one of the main-factors in progression of Alzheimer [11-12]. Natural compounds that have antioxidant properties exhibit their antioxidant effect by quenching free radicals or promoting endogenous antioxidant capacity and some of these stimulate the synthesis of endogenous antioxidant molecules in cell via activation of Nrf/ARE pathways. Therefore, these compounds can be good candidates for the assessment of the AD by scavenging free radicals. Oxidative stress and its sources in AD are illustrated in (Fig. 2).

Figure 2 Antioxidant strategies and sources of oxidative stress in AD.

In our study we also took three cholinesterase inhibitors (Donepezil, Galantamine and Rivastigmine), which are commonly prescribed drugs in Alzheimer, as reference compounds over our natural compounds for drug-likeness studies. Mechanism of action of these drugs by preventing an enzyme called acetylcholinesterase, which breaks down acetylcholine in the brain and enhances antioxidants effects and attenuates oxidative stresses[13-14]. As a result of our investigation, we found that our natural compounds showed promising inhibitory activity also. Some of them were found to have even better activity than prescribed drugs against AD targets. Any compound cannot be directly considered as a drug molecule unless it is validated by several parameters like pharmacokinetic properties, ADME properties, and potential toxicity. Therefore, with the help of various bioinformatics tool, we validated all our compounds.

Molecular docking studies are used to find out the interaction between a ligand/drug and a protein at the atomic level which allows us to characterize the behaviour of our compounds in the binding site of targets as well as to explain fundamental biochemical processes [15]. Each of the natural compounds were docked with all 13 AD associated proteins individually, to determine the best binding affinity using Autodock4.2[16]. Further, these compounds could be useful for the identification and development of new preventive and therapeutic drug against Alzheimer disease .

Materials and Method

Natural Compounds Selection

Forty-five natural compounds were selected as common reported antioxidant natural compounds from various database and literature. All chemical structures of these compounds were sketched in ChemBioDraw Ultra 12.0 (CambridgeSoft) as shown in (Fig. 3).

Figure 3: Chemical structures of the studied compounds.

Basic Pharmacokinetics Parameters Calculation

A compound has to be passed through multiple filters to be considered a novel drug. Most of the compounds that fail in pre-clinical trials do so because they do not show the required pharmacological properties to be a drug molecule [17]. Pharmacokinetics properties such as absorption, distribution, metabolism, excretion, and toxicity (ADMET) has play a very crucial role in development of drug design to the final clinical success of a drug candidate [18]. Therefore, prediction of ADMET properties was done earlier with the aim of decreasing the failure rate of the compound for further process in future. Pharmacokinetics properties of natural compounds such as MW (molecular weight), LogP, HBD(number of hydrogen bond donors), HBA (number of hydrogen bond acceptors), TPSA (topological polar surface area), nrtB (number of rotatable bonds), nViolation (violations of Lipinski's rule of five) [19] were calculated by DruLito (Drug LiknessTool) (www.niper.gov.in/pi_dev_tools/DruLiToWeb/DruLiTo_index.html). and Molinspiration Online tool (<http://www.molinspiration.com/>).

Compound Toxicity Prediction

The compounds toxicities prediction is an important sect of the drug design development process. In silico toxicity assessments are not only faster, but can also reduce the amount of animal experiments. So, calculated LD₅₀ values of all our natural compounds. LD₅₀ value is the amount of doses given to kill 50% of a test population (lab rats or other animals). It is an index determination of medicine and poison's virulence. **The lower the LD₅₀ dose, the greater is the toxicity of the substance.** These LD₅₀ values were calculated by an online tool ProTox[20]. We also determined its carcinogenic, mutagenic and skin irritation properties by using Discovery Studio 2.5 (Accelrys Software Inc., San Diego, CA, USA).

Molecular Docking

Target preparation

All the 13 Alzheimer disease associated targets were downloaded from Protein Data Bank (PDB) (<http://www.rcsb.org/pdb/home/home.do>) and are listed in (Table 2). For crystal structure of each target, the crystallographic water molecules were removed, the missing hydrogen atoms were added and the energy level of all the 13 targets was minimised using swiss_PDB viewer tool [21].

Table 2: 13 Alzheimer disease associated targets

S.No	PDB ID	Protein Name	References
1	1EQG	Cyclooxygenase-1 (COX-1)	[26]
2	1MX1	Human carboxylesterase (hCE-1)	[27]
3	1PBQ	N-methyl-D-aspartate (NMDA)	[28]
4	1Q5K	Glycogen-synthase-kinase-3 β (GSK-3 β)	[29]
5	1QWC	Nitric oxide synthase (NOS)	[30]
6	1UDT	Phosphodiesterase-5 (PD-5)	[31]
7	2FV5	TNF- α converting enzyme (TACE)	[32]
8	3BKL	Angiotensin converting enzyme (ACE)	[33]
9	3G9N	c-Jun N-terminal kinase (JNK)	[34]
10	3QMO	Cyclooxygenase-2 (COX-2)	[35]
11	4B0P	Butyrylcholinesterase (BuChE)	[36]
12	4DJU	β -Site amyloid precursor protein	[37]
13	4EY5	Acetylcholinesterase (AChE)	[38]

Ligand preparation

The structure of all the 45 compounds were drawn in **ChemDraw12** (PerkinElmer Informatics, Waltham, MA, USA) and converted to their 3D form and also geometry of the compounds was optimized in **ChemBio3DUltra12** (PerkinElmer Informatics, Waltham, MA, USA). Finally all compounds were saved in PDB format for further docking studies.

Target Lignad docking

Docking studies yielded crucial information concerning the orientation of the inhibitors in the binding pocket of the target proteins. During the molecular docking process, all the natural compounds bound in the groove of their respective targets. Each of the compounds was docked with all the 13 AD associated targets, hence total 585 dockings were performed (Table 3). Then we used 3D sorting method to filter out the best possible compounds from the pool of 45 natural compounds.

Table 3: Binding energies of all the 45 natural compounds and 03 reference drugs docked with 13Alzheimer disease associated targets.

	1EQG	1MX1	1PBQ	1Q5K	1QWC	1UDT	2FV5	3BKL	3G9N	3QMO	4B0P	4DJU	4EY5
	Affinity (kcal.mol)	Affinity (kcal/mol)	Affinity (kcal.mol)	Affinity (kcal/mol)	Affinity (kcal/mol)	Affinity (kcal/mol)	Affinity (kcal/mol)	Affinity (kcal/mol)	Affinity (kcal/mol)	Affinity (kcal/mol)	Affinity (kcal/mol)	Affinity (kcal/mol)	Affinity (kcal/mol)
Alpha carotene	-7.6	-7.3	-7.2	-8.6	-7.3	-7.5	-6.8	-7.6	-7.5	-7.4	-8	-8.8	-7.1
Apigenin	-9.1	-9.3	-8.4	-8.7	-9.3	-9.4	-8.0	-8.3	-7.8	-7.4	-7.9	-8.4	-8.9
Astaxanthin	-8.2	-7.9	-7.4	-8.7	-6.2	-7.0	-8.0	-10.0	-8.1	-7.4	-8.7	-9.4	-9.2
Beta carotene	-7.9	-7.1	-8.7	-7.4	-9.0	-7.7	-7.6	-7.8	-7.3	-7.9	-8.5	-9.3	-7.1
Canthaxanthin	-8.4	-7.9	-7.8	-8.1	-9.2	-7.2	-8.2	-7.6	-8.7	-7.5	-7.9	-7.4	-6.9
Catechin	-8.7	-9.4	-8.5	-9.7	-9.9	-7.7	-10.1	-10.4	-9.0	-7.6	-10.6	-9.5	-9.6
Chicoric acid	-8	-6.6	-7.3	-8.5	-8.6	-7.1	-8.5	-8.6	-7.4	-7.2	-9.6	-7.3	-8.2
chlorogenic acid	-7.6	-7.4	-6.9	-8.5	-4.8	-6.5	-9.8	-7.8	-7.5	-7.5	-8.3	-7.4	-7.6
Cinnamic acid	-5	-5.5	-4.2	-6.2	-4.7	-6.5	-4.7	-6.1	-4.7	-6.3	-5.4	-5.7	-4.8
Coenzyme Q10	-6.1	-4.8	-4.8	-7.5	-5.1	-6.7	-7.9	-6.8	-6.8	-5.6	-8.2	-7.1	-5.5
Cyanidin	-9.4	-7.2	-8.5	-8.4	-7.9	-7.7	-9.6	-8.9	-7.9	-7.6	-9.2	-8.2	-8.8
Daidzein	-8.5	-7.3	-7.8	-8.4	-7	-8.6	-9.3	-8.2	-7.7	-8.3	-8.3	-8.7	-8.2
Delphinidin	-8.1	-7.9	-7.6	-9.0	-8.6	-7.2	-9.6	-8.3	-8.4	-9.2	-9.3	-8.3	-8.6
Ellagic acid	-7.3	-7.5	-8.2	-9.4	-8.4	-9.7	-8.3	-8.3	-7.6	-8.1	-10.5	-8.1	-9.7
Epicatechin	-9	-7.4	-7.9	-8.7	-9.7	-9.5	-9.5	-8.3	-7.5	-8.9	-8.9	-8.2	-8.2
Epigallocatechin	-7.9	-7.5	-7.5	-8.1	-6.9	-9.6	-8.3	-8.3	-7.5	-9	-8.8	-7.7	-7.9
Eriodictyol	-9.5	-7.6	-7.8	-8.7	-7	-9.5	-9.8	-8.4	-7.6	-9.4	-9.4	-8.2	-8.3
Gallic acid	-6.2	-5.6	-5.8	-6	-6.2	-6.1	-6.9	-6.3	-5.8	-5.2	-6.4	-5.5	-6.4
Galocatechin	-7.9	-7.5	-7.4	-8.2	-6.9	-9.6	-7.4	-8.2	-7.4	-7.6	-9.2	-7.8	-8.4

Genistein	-7.7	-7.4	-8.7	-8.8	-9.6	-7.2	-9	-8.3	-8	-7.8	-7.9	-9.1	-8.6
Glycitein	-7.4	-8.1	-7.5	-9.1	-6.8	-7.8	-7.9	-9.4	-7.2	-7.3	-8.1	-10.2	-9.1
Hesperetin	-8.2	-7.6	-8.3	-8.4	-7.1	-7.2	-9.2	-8.4	-7.9	-9.2	-9.1	-8.4	-8.4
Iodide	-4	-3.9	-4.6	-4.3	-4.7	-3.5	-5.1	-4.4	-4.3	-3.8	-4.5	-4.1	-3.5
Isorhamnetin	-9.5	-7	-7.6	-8.8	-7.3	-8.5	-8.9	-7.8	-8	-9	-9.2	-8.4	-7.3
Kaempferol	-7.7	-7.2	-7.4	-8.8	-6.8	-8.7	-9.0	-8.2	-8.2	-8.9	-7.8	-8.5	-8.9
Lutein	-8.6	-8.4	-6.5	-7.5	-7.8	-7.7	-9.3	-7.6	-8	-7.1	-8.6	-8.9	-7.3
Luteolin	-8	-7.6	-8.6	-8.7	-9.0	-9.8	-9.7	-8.5	-7.8	-9.2	-9.7	-8.4	-8.6
Lycopene	-6.4	-6.6	-6.6	-6.2	-1.9	-7.4	-8.0	-7.8	-6.8	-6.2	-6.8	-7.1	-6.2
Malvidin	-8.5	-6.8	-7.3	-8.5	-8.2	-7.5	-8.7	-8	-7.5	-8.8	-8.9	-8.1	-7.9
Melatonin	-7.5	-6.5	-6.9	-7.1	-5.5	-7.9	-6.1	-7.2	-6.4	-6.8	-7.9	-7	-7.2
Myricetin	-9.2	-7.1	-7.6	-8.9	-7.1	-6.5	-8	-8.3	-8	-8	-9.4	-7.9	-8.5
Naringenin	-8.5	-7.3	-7.5	-8.6	-9.5	-9.5	-9	-8.3	-7.6	-9	-9.1	-8.2	-8.5
Pelargonidin	-8.3	-8.1	-9.1	-9.7	-10.1	-6.9	-8	-9.4	-9	-7.9	-10.1	-9	-10.3
Peonidin	-7.1	-7.3	-7.6	-8.4	-9.2	-9	-9.4	-8.1	-7.6	-9.2	-9	-8.1	-8.9
Petunidin	-8	-7.1	-7.6	-9.0	-8.6	-9.4	-8.8	-8.2	-8.4	-7.6	-9.3	-8.2	-8
Pterostilbene	-7.2	-6.4	-7	-7.5	-6.5	-8.4	-7.8	-7.5	-6.2	-7.7	-7	-7.6	-7.5
Quercetin	-9.5	-7.1	-7.6	-8.5	-7.3	-9.4	-9.2	-8.5	-8.7	-8.4	-9.4	-8.2	-8.5
Resveratrol	-6.5	-6.5	-6.9	-7.3	-8.5	-6.4	-8.6	-7.2	-6.4	-6.5	-7.6	-7.4	-8
Rosmarinic acid	-7.9	-7.4	-5.8	-8.5	-7.8	-7.1	-8.3	-8.5	-5.9	-8.1	-9.2	-7.4	-8.2
Salicyclic acid	-5.5	-5.8	-5.7	-5.9	-4.9	-5.4	-6.2	-6.2	-5.2	-5.4	-5.7	-5.1	-6.3
Tangeritin	-6.8	-6.8	-7.8	-8	-6.8	-9	-8.2	-7.8	-7.6	-7.4	-7.1	-8.2	-8
Theaflavin	-9.8	-8.6	-10.8	-11.4	-8.9	-8	-11.2	-11.3	-8.9	-9.3	-10.2	-10.8	-11.1
Vitamin C	-5.1	-5.1	-5.3	-5.4	-5.8	-4.8	-6.7	-6.1	-5.1	-5.6	-5.8	-5.5	-5.3
Vitamin E	-6.8	-5.7	-7.3	-5.4	-4.7	-5.2	-4.1	-5	-5	-5.2	-5.9	-3.7	-5
Zeaxanthin	-7.8	-7.8	-7.5	-8	-8.2	-6.9	-7.8	-8.7	-8.3	-7.2	-8.4	-9.6	-7.9
Drugs commonly prescribed in Alzheimer disease													
Donepezil	-8.9	-6.5	-7.5	-8.9	-9.8	-6.7	-6.4	-8.1	-8.6	-7.6	-7.7	-8.6	-7.5
Galantamine	-7.4	-6.5	-5.7	-6.8	-8.0	-5.8	-6.4	-7.7	-6.7	-6.8	-6.8	-6.3	-6.5
Rivastigmine	-6.4	-6.1	-6.6	-6.7	-8.3	-5.2	-7.2	-6.1	-6.1	-5.9	-7.2	-6.2	-6.2

This method can be defined as filtering out the best using 3 levels of selection, first on the basis of the score (docking), second in addition to ranks the compounds on the basis of interaction with number of receptors and finally eliminating those that violate the minimum criterion for RO5 (Lipinski Rule of Five) and toxicity. The docking interactions were visualized with PYMOL molecular graphics system, version 1.7.4.4 (Schrödinger, LLC, and Portland, OR, USA) and Maestro Visualizer (Maestro, Schrödinger, LLC, New York, NY, 2017.). The docking studies were performed using Autodock4.0[22]. The inhibition constant (K_i) of natural compounds against Alzheimer associated targets was calculated from docking energy using the following equation:

$$K_i = \exp(\Delta G * 1000)/RT)$$

Where ΔG = docking energy; $R = 1.98719 \text{ cal K}^{-1} \text{ mol}^{-1}$, $T = 298.15^\circ\text{K}$, K_i = inhibition constant (nM)

Results

Pharmacokinetics Properties

Pharmacokinetics properties of natural compounds to be considered as drug candidates were based on Lipinski's rule of five. This rule is formulated for most orally administered drugs, it uses four criteria to determine if a molecule is druglike; to have a molecular weight of ≤ 500 , a LogP (logarithm of partition coefficient) ≤ 5 , five or fewer hydrogen bond donor sites, and ten or fewer hydrogen bond acceptor sites. Molecules violating more than one of these rules may have problems with bioavailability. The entire set of compounds well followed the RO5 (Rule of 5) except 15 of the compounds, out of which eight compounds (*Alpha carotene, Astaxanthin, Beta carotene, Canthaxanthin, Coenzyme Q10, Epigallocatechin, Gallocatechin and Theaflavin*) violating more than one of these rules and seven compounds violating only single rule (*Chlorogenic acid, Delphinidin, Gallic acid, Lycopene, Myricetin, Vitamin C, Vitamin E*) that created the Lipinski's rule violation by having *molecular mass* > 500 , *logP* > 5 and *H – bond doner* > 5 that can create a problem in oral bioavailability.

TPSA analysis checked the bioavailability of natural compounds, As per the Veber's rule for good oral bioavailability, the number of rotatable bond must be ≤ 10 , and TPSA values $\leq 140\text{\AA}$ [23]. The number of rotatable bonds has been shown to be a very good descriptor of oral bioavailability of drugs and has been found better to discriminate between compounds that have oral bioavailability of drugs. Rotatable bond is defined as any single non-ring bond, bounded to non-terminal heavy (ie, non-hydrogen) atom. Amide C–N bonds are not considered because of their high rotational energy barrier [24]. The numbers of rotatable bonds in all of our compounds were found to be appropriate as in reference compounds (Donepezil, Galantamine and Rivastigmine) except four compounds (*Vit E, Chicoric acid, CoenzymeQ10, Lycopene*) have $> 10 \text{ nRB}$. Once TPSA was calculated and it was found that only four compounds

(Chicoric acid, Chlorogenic acid, Rosmarinic acid and Theaflavin) have TPSA values $\leq 140\text{\AA}$, then we calculated percentage of absorption for all the 45 compounds using Zhao et al. formula[25].

$$\text{Percentages of Absorption (\%ABS)} = [109 - (0.3345 \times \text{TPSA})]$$

According to above formula, we calculated percentages of absorption of our compounds and as well as our reference compounds. Compounds (Theaflavin, Chicoric acid, Chlorogenic acid, Myricetin and Rosmarinic acid) have poor absorbance percentage 36.212%, 37.490%, 52.944%, 59.601% and 59.711% respectively, further details are given in (Table 4).

Table 4: Shows the drug likeness of compounds and violation of Lipinski's rule are highlighted in red colour.

S. No.	Ligand	Molecular Formula	Molecular Weight (g/mol)	logP	H-Bond Acceptors	H-Bond Donors	TPSA	% ABS	nRB	nAtom	nViolation
1	Alpha carotene	C ₄₀ H ₅₆	536.44	15.187	0	0	0	109.00	10	96	2
2	Apigenin	C ₁₅ H ₁₀ O ₅	270.05	1.567	1	3	86.99	79.901	1	30	0
3	Astaxanthin	C ₄₀ H ₅₂ O ₄	596.39	9.696	4	2	74.6	84.046	10	96	2
4	Beta carotene	C ₄₀ H ₅₆	536.44	14.734	0	0	0	109.00	10	96	2
5	Catechin	C ₁₅ H ₁₄ O ₆	290.08	0.406	1	5	110.38	72.077	1	35	0
6	Canthaxanthin	C ₄₀ H ₅₂ O ₂	564.4	10.788	2	0	34.14	97.580	10	94	2
7	Chicoric acid	C ₂₂ H ₁₈ O ₁₂	472.06	0.722	8	4	213.78	37.490	11	50	0
8	Chlorogenic acid	C ₁₆ H ₁₈ O ₉	353.09	-0.928	7	5	167.58	52.944	5	42	1
9	Cinnamic acid	C ₉ H ₈ O ₂	147.04	3.423	2	0	40.13	95.576	2	18	0
10	Coenzyme Q10	C ₅₉ H ₉₀ O ₄	862.68	18.454	4	0	52.6	91.405	31	153	2
11	Cyanidin	C ₁₅ H ₁₁ O ₆ ⁺	287.06	0	1	5	101.15	75.165	1	32	0
12	Daidzein	C ₁₅ H ₁₀ O ₄	254.06	2.475	1	2	66.76	86.668	1	29	0
13	Delphinidin	C ₁₅ H ₁₁ O ₇ ⁺	303.05	0	1	6	121.38	68.398	1	33	1
14	Ellagic acid	C ₁₄ H ₆ O ₈	299.99	0.652	8	2	93.06	77.871	0	26	0
15	Epicatechin	C ₁₅ H ₁₄ O ₆	290.08	0.406	1	5	110.38	72.077	1	35	0
16	Epigallocatechin	C ₁₅ H ₁₄ O ₇	306.07	-0.128	1	6	130.61	65.310	1	36	2
17	Eriodictyol	C ₁₅ H ₁₂ O ₆	288.06	0.363	1	4	107.22	73.134	1	33	0

18	Gallic acid	C ₇ H ₆ O ₅	169.01	-0.479	2	3	100.82	75.275	1	17	0
19	Gallocatechin	C ₁₅ H ₁₄ O ₇	306.07	-0.128	1	6	130.61	65.310	1	36	1
20	Genistein	C ₁₅ H ₁₀ O ₅	270.05	1.043	5	3	86.99	79.901	1	30	0
21	Glycitein	C ₁₆ H ₁₂ O ₅	284.07	2.031	1	2	75.99	83.581	2	33	0
22	Hesperetin	C ₁₆ H ₁₄ O ₆	302.08	0.453	1	3	96.22	76.814	2	36	0
23	Iodide	I ⁻	144.14	0.035	1	0	17.07	103.29	4	28	0
24	Isorhamnetin	C ₁₆ H ₁₂ O ₇	316.06	1.471	2	4	116.45	70.047	2	35	0
25	Kaempferol	C ₁₅ H ₁₀ O ₆	286.05	1.915	2	4	107.22	73.134	1	31	0
26	Lutein	C ₄₀ H ₅₆ O ₂	568.43	11.283	2	2	40.46	95.466	10	98	1
27	Luteolin	C ₁₅ H ₁₀ O ₆	286.05	1.033	1	4	107.22	73.134	1	31	0
28	Lycopene	C ₄₀ H ₅₆	536.44	14.586	0	0	0	109.00	16	96	1
29	Malvidin	C ₁₇ H ₁₅ O ₇ ⁺	331.08	0	1	4	99.38	75.757	3	39	0
30	Melatonin	C ₁₃ H ₁₆ N ₂ O ₂	232.12	1.254	3	2	50.36	92.154	5	33	0
31	Myricetin	C ₁₅ H ₁₀ O ₈	318.04	0.847	2	6	147.68	59.601	1	33	1
32	Naringenin	C ₁₅ H ₁₂ O ₅	272.07	0.897	1	3	86.99	79.901	1	32	0
33	Pelargonidin	C ₁₅ H ₁₁ O ₅ ⁺	271.06	0	1	4	80.92	81.932	1	31	0
34	Peonidin	C ₁₆ H ₁₃ O ₆ ⁺	301.07	0	6	4	90.15	78.844	2	35	0
35	Petunidin	C ₁₆ H ₁₃ O ₇ ⁺ (Cl ⁻)	317.07	0	1	5	110.38	72.077	2	36	0
36	Pterostilbene	C ₁₆ H ₁₆ O ₃	256.11	2.69	3	1	38.69	96.058	4	35	0
37	Quercetin	C ₁₅ H ₁₀ O ₇	302.04	1.381	2	5	127.45	66.367	1	32	0
38	Resveratrol	C ₁₄ H ₁₂ O ₃	228.08	3.436	0	3	60.69	88.699	2	29	0
39	Rosmarinic acid	C ₁₈ H ₁₆ O ₈	359.08	1.602	4	4	147.35	59.711	7	41	0
40	Salicylic acid	C ₇ H ₆ O ₃	137.02	0.8	2	1	60.36	88.809	1	15	0
41	Tangeritin	C ₂₀ H ₂₀ O ₇	372.12	2.236	1	0	72.45	84.765	6	47	0
42	Theaflavin	C ₂₉ H ₂₄ O ₁₂	564.13	-0.216	4	9	217.6	36.212	2	65	2
43	Vitamin C	C ₆ H ₈ O ₆	175.02	-1.813	6	2	83.83	80.958	2	19	0
44	Vitamin E	C ₂₉ H ₅₀ O ₂	430.38	10.938	0	1	29.46	99.145	12	81	1
45	Zeaxanthin	C ₄₀ H ₅₆ O ₂	568.43	10.564	2	2	40.46	95.466	10	98	1
Three Cholinesterase inhibitors are commonly prescribed in Alzheimer disease											
1	Donepezil	C ₂₄ H ₃₀ N ₃ O ₃ ⁺	380.50	3.65	1	4	39.97	95.23	6	58	0
2	Galantamine	C ₁₇ H ₁₂ N ₃ O ₃ ⁺	288.36	1.54	2	4	43.13	94.14	1	43	0
3	Rivastigmine	C ₁₄ H ₂₃ N ₂ O ₂ ⁺	251.34	2.28	1	4	33.98	97.27	6	41	0

%ABS- Percentage of Absorption

nAtom- Number of Atoms

H-BD < 5

TPSA- Topological Polar Surface Area

nViolation- Violation of Lipinski's rule

H-BA < 10

nrtB- Number of rotatable Atoms

XlogP ≤ 5

MW < 500

Toxicity Prediction

The computational prediction of toxicities, drug score profiles of natural compounds are promising. An online software PROTOX was used for the prediction of the LD₅₀ of the new compounds. Most of the compounds in our study fell in non-toxic zone (above the 1000 *mg/kg*) except Lutein (10 *mg/kg*), Myricetin (159 *mg/kg*), Quercetin (159 *mg/kg*), Salicylic acid (480 *mg/kg*) and Zeaxanthin (10 *mg/kg*), results are shown in the graph in (Fig. 4). The mutagenicity, carcinogenicity and skin irritation properties were also predicted and it was found that 05 compounds are mutagenic, 07 compounds are carcinogenic, 38 compounds are very sensitive to skin but 09 of these compounds may cause severe skin irritation problems. Results are listed in (Table 5).

Figure 4 Histogram representation of LD₅₀ values of natural compounds compared with commonly prescribes drugs.

Table 5: Shows the toxicity of compounds and various toxicities are highlighted in red colour.

S. no.	Compound	Carcinogenicity	Mutagenicity	Skin Irritation	Skin Sensitization	Biodegradability
1	Alpha carotene	Carcinogen	Non mutagen	Severe	Weak	Degradable
2	Apigenin	Non carcinogen	Non mutagen	None	Strong	Non degradable
3	Astaxanthin	Non carcinogen	Non mutagen	Mild	Weak	Degradable
4	Beta carotene	Carcinogen	Non mutagen	Severe	Weak	Degradable
5	Catechin	Non carcinogen	Non mutagen	None	Strong	Non degradable
6	Canthaxanthin	Carcinogen	Non mutagen	Severe	Weak	Degradable
7	Chicoric acid	Non carcinogen	Non mutagen	None	Strong	Degradable
8	Chlorogenic acid	Non carcinogen	Non mutagen	Mild	None	Degradable
9	Cinnamic acid	Carcinogen	Non mutagen	Mild	Strong	Degradable
10	Coenzyme Q10	Carcinogen	Non mutagen	Severe	None	Degradable
11	Cyanidin	Non carcinogen	Non mutagen	None	Strong	Non degradable
12	Daidzein	Non carcinogen	Non mutagen	None	Strong	Non degradable
13	Delphinidin	Non carcinogen	Non mutagen	None	Strong	Non degradable
14	Ellagic acid	Non carcinogen	Non mutagen	Mild	Weak	Non degradable
15	Epicatechin	Non carcinogen	Non mutagen	None	Strong	Non degradable
16	Epigallocatechin	Non carcinogen	Non mutagen	None	Strong	Non degradable
17	Eriodictyol	Non carcinogen	Non mutagen	None	Strong	Non degradable
18	Gallic acid	Non carcinogen	Non mutagen	None	Strong	Degradable
19	Gallocatechin	Non carcinogen	Non mutagen	None	Strong	Non degradable
20	Genistein	Non carcinogen	Non mutagen	None	Strong	Non degradable
21	Glycitein	Non carcinogen	Non mutagen	None	None	Degradable
22	Hesperetin	Non carcinogen	Non mutagen	None	Strong	Degradable

23	Iodide	Non carcinogen	Non mutagen	Severe	Weak	Degradable
24	Isorhamnetin	Non carcinogen	Mutagen	None	Strong	Non degradable
25	Kaempferol	Non carcinogen	Mutagen	None	Strong	Non degradable
26	Lutein	Non carcinogen	Non mutagen	Severe	Weak	Degradable
27	Luteolin	Non carcinogen	Non mutagen	None	Strong	Non degradable
28	Lycopene	Carcinogen	Non mutagen	Severe	Weak	Degradable
29	Malvidin	Non carcinogen	Non mutagen	None	Strong	Non degradable
30	Melatonin	Non carcinogen	Non mutagen	None	None	Non degradable
31	Myricetin	Non carcinogen	Mutagen	None	Strong	Non degradable
32	Naringenin	Non carcinogen	Non mutagen	None	Strong	Non degradable
33	Pelargonidin	Non carcinogen	Non mutagen	None	Strong	Non degradable
34	Peonidin	Non carcinogen	Non mutagen	None	Strong	Non degradable
35	Petunidin	Non carcinogen	Non mutagen	None	Strong	Non degradable
36	Pterostilbene	Non carcinogen	Mutagen	None	Strong	Non degradable
37	Quercetin	Non carcinogen	Non mutagen	None	Strong	Non degradable
38	Resveratrol	Non carcinogen	Non mutagen	None	Strong	Non degradable
39	Rosmarinic acid	Non carcinogen	Non mutagen	None	Strong	Non degradable
40	Salicylic acid	Non carcinogen	Non mutagen	None	None	Degradable
41	Tangeritin	Non carcinogen	Non mutagen	None	Strong	Degradable
42	Theaflavin	Non carcinogen	Non mutagen	None	Strong	Non degradable
43	Vitamin C	Non carcinogen	Non mutagen	None	None	Degradable
44	Vitamin E	Carcinogen	Non mutagen	Severe	None	Non degradable
45	Zeaxanthin	Non carcinogen	Non mutagen	Severe	Weak	Degradable

Molecular docking Studies

To ensure the interaction between the natural compounds and Alzheimer disease associated targets, we performed molecular docking analysis using Autodock4.2. Each of the compounds was docked with all the 13 Alzheimer disease associated targets individually. These compounds showed very good binding affinity with all the 13 Alzheimer associated targets.

Among all of the compounds only 09 compounds interacted with maximum number of targets, such as **Theaflavin** showed maximum interactions, as it interacted with 11 Alzheimer associated targets (1EQG, 1MX1, 1PBQ, 1Q5K, 2FV5, 3BKL, 3G9N, 3QMO, 4B0P, 4DJU and 4EY5); whereas compound **Catechin** interacted with 10 targets (1MX1, 1PBQ, 1Q5K, 1QWC, 2FV5, 3BKL, 3G9N, 4B0P, 4DJU and 4EY5), **Pelargonidin** interacted with 05 targets (1Q5K, 1QWC, 3BKL, 4B0P and 4EY5), **Luteolin** intercalated with 05 targets (1PBQ, 1UDT, 2FV5, 3QMO and 4B0P),

Ellagic acid compound interacted with 04 targets (1Q5K, 1UDT, 4B0P and 4EY5), **Eriodictyol** intercalated with 04 targets (1EQG, 1UDT, 2FV5 and 3QMO), **Glycitein** intercalated with 04 targets (1MX1, 1Q5K, 3BKL and 4DJU), **Quercetin** intercalated with 03 targets (1EQG, 1UDT and 3G9N) and **Astaxanthin** intercalated with 03 targets (3BKL, 4DJU and 4EY5). Even though compounds **Astaxanthin** and **Theaflavin** showed very good binding affinity, we did not consider them for further docking analysis because they did not comply with the Lipinski's rule. **Astaxanthin** has greater molecular mass (596.39 Daltons) and greater log P (9.696) value, whereas **Theaflavin** has greater molecular mass (564.13 g/mol) and more than five H-bond donor. The range of the binding affinities of all the compounds lies between -4.00 kcal/mol to -11.4 kcal/mol. In addition, the residues surrounding the ligands (within 4 Å) in all docking results provide short range polar interactions that stabilize the formation of complex (with the help of delocalization of charges on ligands). It is not possible to show all the binding poses but we have shown 07 poses which have maximum binding affinity among all of them (Fig. 5). The inhibitor constant (K_i) is an indicator of the effectiveness of an inhibitor, with a greatly potent inhibitor being indicated by a low K_i because smaller the K_i , the greater the binding affinity and the smaller amount of medication needed in order to inhibit the activity of that enzyme [34]. All of our compounds were found to have a very small K_i value except compound *Cinnamic acid*, (with 1EQG, 1PBQ, 1QWC, 2FV5, 3G9N, 4B0P and 4EY5), *Chlorogenic acid* (with 1QWC), *Coenzyme Q10* (with 1MX1, 1PBQ and 1QWC), *Gallic acid* (with 3QMO), Iodide (with all targets), *Lycopene* (with 1QWC), *Salicylic acid* (with 1QWC, 1UDT, 3G9N, 3QMO and 4DJU), *Vitamin C* (with 1EQG, 1MX1, 1PBQ, 1Q5K, 1UDT, 3G9N and 4EY5), *Vitamin E* (with 1Q5K, 1QWC, 1UDT, 2FV5, 3BKL, 3G9N, 3QMO, 4DJU and 4EY5) and all three drugs commonly prescribed in Alzheimer disease (*Donepezil*, *Galantamine* and *Rivastigmine*) that have very poor K_i values with 4DJU (Table 6). In this way, all of these results suggest that our natural compounds potentially interfere with Alzheimer associated targets, which should prompt further investigations to expose the mechanism of our compounds against Alzheimer disease in vivo.

Figure 5 Molecular docking poses of the top seven representative compounds: Crystallographic structure of (A) **Catechin** complexed to *Butyrylcholinesterase*(BuChE)(Pdb id: 4BOP), (B) **Ellagic acid** complexed to *Butyrylcholinesterase* (BuChE) (Pdb id: 4BOP), (C) **Eriodictyol** complexed to *TNF- α converting enzyme* (TACE)(Pdb id: 2FV5), (D) **Glycitein** complexed to *β -Site amyloid precursor protein* (Pdb id: 4DJU), (E) **Luteolin** complexed to *TNF- α converting enzyme* (Pdb id: 2FV5), (F) **Pelagonidin** complexed to *Acetylcholinesterase* (AChE) (Pdb id: 4EY5), (G) **Quercetin** complexed to *Cyclooxygenase-1* (COX-1) (Pdb id: 1EQG).

Table 6: Calculated K_i (nM) value from docking energy of 45 natural compounds against 13 Alzheimer disease associated targets. Compounds that have very poor K_i values are highlighted in grey colour.

Compound Names	1EQG	1MX1	1PBQ	1Q5K	1QWC	1UDT	2FV5	3BKL	3G9N	3QMO	4B0P	4DJU	4EY5
Alpha carotene	4.46E-06	4.46E-06	5.28E-06	4.97E-07	4.46E-06	3.18E-06	1.04E-05	2.69E-06	3.18E-06	3.76E-06	1.37E-06	3.54E-07	6.25E-06
Apigenin	2.14E-07	1.52E-07	6.96E-07	4.20E-07	1.52E-07	1.29E-07	1.37E-06	8.24E-07	1.92E-06	3.76E-06	1.62E-06	6.96E-07	2.99E-07
Astaxanthin	9.76E-07	1.62E-06	3.76E-06	4.20E-07	2.85E-05	7.39E-06	1.37E-06	4.68E-08	1.16E-06	3.76E-06	4.20E-07	1.29E-07	1.80E-07
Beta carotene	1.62E-06	6.25E-06	4.20E-07	3.76E-06	2.53E-07	2.27E-06	2.69E-06	1.92E-06	4.46E-06	1.62E-06	5.88E-07	1.52E-07	6.25E-06
Canthaxanthin	6.96E-07	1.62E-06	1.92E-06	1.16E-06	1.80E-07	5.28E-06	9.76E-07	2.69E-06	4.20E-07	3.18E-06	1.62E-06	3.76E-06	8.75E-06
Catechin	4.20E-07	1.29E-07	5.88E-07	7.76E-08	5.54E-08	2.27E-06	3.95E-08	2.38E-08	2.53E-07	2.69E-06	1.70E-08	1.09E-07	9.19E-08
Chicoric acid	1.37E-06	1.45E-05	4.46E-06	5.88E-07	4.97E-07	6.25E-06	5.88E-07	4.97E-07	3.76E-06	5.28E-06	9.19E-08	4.46E-06	9.76E-07
Chlorogenic acid	2.69E-06	3.76E-06	8.75E-06	5.88E-07	0.000303	1.72E-05	6.55E-08	1.92E-06	3.18E-06	3.18E-06	8.24E-07	3.76E-06	2.69E-06
Cinnamic acid	0.00021625	9.30E-05	0.000834	2.85E-05	0.000359	1.72E-05	0.000359	3.38E-05	0.000359	2.41E-05	0.00011	6.64E-05	0.000303
Coenzyme Q10	3.38E-05	0.000303	0.000303	3.18E-06	0.000183	1.23E-05	1.62E-06	1.04E-05	1.04E-05	7.85E-05	9.76E-07	6.25E-06	9.30E-05
Cyanidin	1.29E-07	5.28E-06	5.88E-07	6.96E-07	1.62E-06	2.27E-06	9.19E-08	2.99E-07	1.62E-06	2.69E-06	1.80E-07	9.76E-07	3.54E-07
Daidzein	5.88E-07	4.46E-06	1.92E-06	6.96E-07	7.39E-06	4.97E-07	1.52E-07	9.76E-07	2.27E-06	8.24E-07	8.24E-07	4.20E-07	9.76E-07
Delphinidin	1.16E-06	1.62E-06	2.69E-06	2.53E-07	4.97E-07	5.28E-06	9.19E-08	8.24E-07	6.96E-07	1.80E-07	1.52E-07	8.24E-07	4.97E-07
Ellagic acid	4.46E-06	3.18E-06	9.76E-07	1.29E-07	6.96E-07	7.76E-08	8.24E-07	8.24E-07	2.69E-06	1.16E-06	2.01E-08	1.16E-06	7.76E-08
Epicatechin	2.53E-07	3.76E-06	1.62E-06	4.20E-07	7.76E-08	1.09E-07	1.09E-07	8.24E-07	3.18E-06	2.99E-07	2.99E-07	9.76E-07	9.76E-07
Epigallocatechin	1.62E-06	3.18E-06	3.18E-06	1.16E-06	8.75E-06	9.19E-08	8.24E-07	8.24E-07	3.18E-06	2.53E-07	3.54E-07	2.27E-06	1.62E-06
Eriodictyol	1.09E-07	2.69E-06	1.92E-06	4.20E-07	7.39E-06	1.09E-07	6.55E-08	6.96E-07	2.69E-06	1.29E-07	1.29E-07	9.76E-07	8.24E-07
Gallic acid	2.85E-05	7.85E-05	5.60E-05	4.00E-05	2.85E-05	3.38E-05	8.75E-06	2.41E-05	5.60E-05	0.000154	2.04E-05	9.30E-05	2.04E-05
Gallocatechin	1.62E-06	3.18E-06	3.76E-06	9.76E-07	8.75E-06	9.19E-08	3.76E-06	9.76E-07	3.76E-06	2.69E-06	1.80E-07	1.92E-06	6.96E-07
Genistein	2.27E-06	3.76E-06	4.20E-07	3.54E-07	9.19E-08	5.28E-06	2.53E-07	8.24E-07	1.37E-06	1.92E-06	1.62E-06	2.14E-07	4.97E-07
Glycitein	3.76E-06	1.16E-06	3.18E-06	2.14E-07	1.04E-05	1.92E-06	1.62E-06	1.29E-07	5.28E-06	4.46E-06	1.16E-06	3.34E-08	2.14E-07
Hesperetin	9.76E-07	2.69E-06	8.24E-07	6.96E-07	6.25E-06	5.28E-06	1.80E-07	6.96E-07	1.62E-06	1.80E-07	2.14E-07	6.96E-07	6.96E-07
Iodide	0.00116939	0.001384	0.000425	0.000705	0.000359	0.002719	0.000183	0.000595	0.000705	0.001639	0.000503	0.000988	0.002719
Isorhamnetin	1.09E-07	7.39E-06	2.69E-06	3.54E-07	4.46E-06	5.88E-07	2.99E-07	1.92E-06	1.37E-06	2.53E-07	1.80E-07	6.96E-07	4.46E-06
Kaempferol	2.27E-06	5.28E-06	3.76E-06	3.54E-07	1.04E-05	4.20E-07	2.53E-07	9.76E-07	9.76E-07	2.99E-07	1.92E-06	5.88E-07	2.99E-07
Lutein	4.97E-07	6.96E-07	1.72E-05	3.18E-06	1.92E-06	2.27E-06	1.52E-07	2.69E-06	1.37E-06	6.25E-06	4.97E-07	2.99E-07	4.46E-06
Luteolin	1.37E-06	2.69E-06	4.97E-07	4.20E-07	2.53E-07	6.55E-08	7.76E-08	5.88E-07	1.92E-06	1.80E-07	7.76E-08	6.96E-07	4.97E-07
Lycopene	2.04E-05	1.45E-05	1.45E-05	2.85E-05	0.040484	3.76E-06	1.37E-06	1.92E-06	1.04E-05	2.85E-05	1.04E-05	6.25E-06	2.85E-05
Malvidin	5.88E-07	1.04E-05	4.46E-06	5.88E-07	9.76E-07	3.18E-06	4.20E-07	1.37E-06	3.18E-06	3.54E-07	2.99E-07	1.16E-06	1.62E-06
Melatonin	3.18E-06	1.72E-05	8.75E-06	6.25E-06	9.30E-05	1.62E-06	3.38E-05	5.28E-06	2.04E-05	1.04E-05	1.62E-06	7.39E-06	5.28E-06

Myricetin	1.80E-07	6.25E-06	2.69E-06	2.99E-07	6.25E-06	1.72E-05	1.37E-06	8.24E-07	1.37E-06	1.37E-06	1.29E-07	1.62E-06	5.88E-07
Naringenin	5.88E-07	4.46E-06	3.18E-06	4.97E-07	1.09E-07	1.09E-07	2.53E-07	8.24E-07	2.69E-06	2.53E-07	2.14E-07	9.76E-07	5.88E-07
Pelargonidin	8.24E-07	1.16E-06	2.14E-07	7.76E-08	3.95E-08	8.75E-06	1.37E-06	1.29E-07	2.53E-07	1.62E-06	3.95E-08	2.53E-07	2.82E-08
Peonidin	6.25E-06	4.46E-06	2.69E-06	6.96E-07	1.80E-07	2.53E-07	1.29E-07	1.16E-06	2.69E-06	1.80E-07	2.53E-07	1.16E-06	2.99E-07
Petunidin	1.37E-06	6.25E-06	2.69E-06	2.53E-07	4.97E-07	1.29E-07	3.54E-07	9.76E-07	6.96E-07	2.69E-06	1.52E-07	9.76E-07	1.37E-06
Pterostilbene	5.28E-06	2.04E-05	7.39E-06	3.18E-06	1.72E-05	6.96E-07	1.92E-06	3.18E-06	2.85E-05	2.27E-06	7.39E-06	2.69E-06	3.18E-06
Quercetin	1.09E-07	6.25E-06	2.69E-06	5.88E-07	4.46E-06	1.09E-07	1.80E-07	5.88E-07	4.20E-07	6.96E-07	1.29E-07	9.76E-07	5.88E-07
Resveratrol	1.72E-05	1.72E-05	8.75E-06	4.46E-06	5.88E-07	2.04E-05	4.97E-07	5.28E-06	2.04E-05	1.72E-05	2.69E-06	3.76E-06	1.37E-06
Rosmarinic acid	1.62E-06	3.76E-06	5.60E-05	5.88E-07	1.92E-06	6.25E-06	8.24E-07	5.88E-07	4.73E-05	1.16E-06	1.80E-07	3.76E-06	9.76E-07
Salicyclic acid	9.30E-05	5.60E-05	6.64E-05	4.73E-05	0.000256	0.00011	2.85E-05	2.85E-05	0.000154	0.00011	6.64E-05	0.000183	2.41E-05
Tangeritin	1.04E-05	1.04E-05	1.92E-06	1.37E-06	1.04E-05	2.53E-07	9.76E-07	1.92E-06	2.69E-06	3.76E-06	6.25E-06	9.76E-07	1.37E-06
Theaflavin	6.55E-08	4.97E-07	1.21E-08	4.40E-09	2.99E-07	1.37E-06	6.17E-09	5.21E-09	2.99E-07	1.52E-07	3.34E-08	1.21E-08	7.30E-09
Vitamin C	0.00018266	0.000183	0.00013	0.00011	5.60E-05	0.000303	1.23E-05	3.38E-05	0.000183	7.85E-05	5.60E-05	9.30E-05	0.00013
Vitamin E	1.04E-05	6.64E-05	4.46E-06	0.00011	0.000359	0.000154	0.000988	0.000216	0.000216	0.000154	4.73E-05	0.00194	0.000216
Zeaxanthin	1.92E-06	1.92E-06	3.18E-06	1.37E-06	9.76E-07	8.75E-06	1.92E-06	4.20E-07	8.24E-07	5.28E-06	6.96E-07	9.19E-08	1.62E-06
Drugs commonly prescribed in Alzheimer disease													
Donepezil	3.18E-06	4.46E-06	5.28E-06	4.97E-07	4.46E-06	3.18E-06	1.04E-05	2.69E-06	3.18E-06	3.76E-06	1.37E-06	1.000001	6.25E-06
Galantamine	1.29E-07	1.52E-07	6.96E-07	4.20E-07	1.52E-07	1.29E-07	1.37E-06	8.24E-07	1.92E-06	3.76E-06	1.62E-06	1.000001	2.99E-07
Rivastigmine	7.39E-06	1.62E-06	3.76E-06	4.20E-07	2.85E-05	7.39E-06	1.37E-06	4.68E-08	1.16E-06	3.76E-06	4.20E-07	1.000000	1.80E-07

Discussion

Natural products have been used since ancient times and are well recognized as sources of drugs in several human ailments. The healing ability of these herbs and medicinal plants draw attention to study natural products as a potentially valuable resource of drug molecules, they are evolutionarily optimized as drug-like molecules and remain the best sources of drugs and drug leads [39][40]. In our study, we chose 45 natural compounds that have remarkable antioxidant property and act mainly by scavenging free radical species. In recent years, significant data have been gathered, indicating the level of oxidative stress increase in the brain in AD condition. This may have a role in the pathogenesis of neuron degeneration and death [41]. Thus, protection and inhibition against oxidative stress may be considered an important criterion in the

development of anti-Alzheimer agents. Therefore, treatment with these antioxidant agents might prevent or reduce the progression of AD. These natural compounds may prove to be novel anti-Alzheimer agents. In order to exploit all the properties for a compound to behave as a drug, the study was done in silico by using different computational tools based on Chemo-informatics or Bioinformatics. The drug-like property predictions showed that most of the compounds followed the Lipinski's rule of five and ADMET. Finally, it can be seen from our docking studies also that the compounds exhibit a strong interaction with Alzheimer associated targets. As this is an insilico study, therefore one should not forget to consider the complex biological metabolic processes during the onset of Alzheimer. The interaction parameter may vary due to multiple interactions in complex system which is another subject of consideration. These results suggest that these compounds may be considered to be a kind of novel anti-Alzheimer's Disease drug agents, which are multi target-directed ligands with not only antioxidant activity but also inhibitory and neuroprotective activities. Molecular docking and pharmacokinetics studies showed that most of our compounds fulfil the requirements for an anti-Alzheimer drug, such as ADMET, RO5, non toxicity, binding affinity, inhibition constants, antioxidant, and neuroprotective inhibitory properties and good interaction with Alzheimer associate targets. In this way these results suggest that natural compounds potentially interfere with Alzheimer associated targets, which should prompt further investigations to expose the mechanism of our compounds against Alzheimer disease in vivo. Therefore, we recommend them for future in vivo studies and possible clinical trials.

Conclusion

Several natural products are used alone or in combination with other neuroprotective compounds to improve memory and cognition in AD patients as supported by various experimental studies. Altogether, this pioneering study was used to preliminarily investigate the potential compounds (drug candidates) from natural products and conventional docking study to analyze the best docked ligands permitted us to know the binding mode of compounds. Binding energies of the drug-targets interactions are important to describe how fit the drug binds to the target macromolecule (13 Alzheimer disease associated targets). Further studies are essential to explore the target specific effect of these natural compounds on various signalling pathways, mode of action in various brain regions, the ability to cross the blood brain barrier and the mechanism behind the synergistic action of the antioxidant agents on the target. Using novel Pharmaceutical engineering and medicinal chemistry approach to prepare novel formulations or design new compounds based on natural templates, opens up a new window into using natural therapeutic agents against AD.

Acknowledgements

The authors are grateful to the Centre for Interdisciplinary Research in Basic Sciences (CIRBSc), Jamia Millia Islamia for providing the research infrastructure.

Aftab Alam is supported by a research fellowship of the University Grants Commission, Government of India., SA and MZM are supported by the Indian Council of Medical Research under SRF (Senior Research Fellowship).

Disclosure

The authors report no conflicts of interests in this work.

References:

- [1] Y. Feng and X. Wang, "Antioxidant Therapies for Alzheimer's Disease," *Oxid. Med. Cell. Longev.*, vol. 2012, pp. 1–17, 2012.
- [2] M. A. Smith *et al.*, "Advanced Maillard reaction end products are associated with Alzheimer disease pathology," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 91, no. 12, pp. 5710–5714, Jun. 1994.
- [3] M. A. Smith, P. L. Richey Harris, L. M. Sayre, J. S. Beckman, and G. Perry, "Widespread peroxynitrite-mediated damage in Alzheimer's disease," *J. Neurosci. Off. J. Soc. Neurosci.*, vol. 17, no. 8, pp. 2653–2657, Apr. 1997.
- [4] T. J. Montine, V. Amarnath, M. E. Martin, W. J. Strittmatter, and D. G. Graham, "E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures," *Am. J. Pathol.*, vol. 148, no. 1, pp. 89–93, Jan. 1996.
- [5] L. M. Sayre, D. A. Zelasko, P. L. Harris, G. Perry, R. G. Salomon, and M. A. Smith, "4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease," *J. Neurochem.*, vol. 68, no. 5, pp. 2092–2097, May 1997.
- [6] C. D. Smith *et al.*, "Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 88, no. 23, pp. 10540–10543, Dec. 1991.
- [7] M. A. Smith *et al.*, "Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease," *J. Neurochem.*, vol. 64, no. 6, pp. 2660–2666, Jun. 1995.
- [8] J. Manivannan, T. Silambarasan, R. Kadarkarairaj, and B. Raja, "Systems pharmacology and molecular docking strategies prioritize natural molecules as cardioprotective agents," *RSC Adv*, vol. 5, no. 94, pp. 77042–77055, 2015.
- [9] V. Sharma, P. C. Sharma, and V. Kumar, "In Silico Molecular Docking Analysis of Natural Pyridoacridines as Anticancer Agents," *Adv. Chem.*, vol. 2016, pp. 1–9, 2016.
- [10] D.-Y. Choi, Y.-J. Lee, J. T. Hong, and H.-J. Lee, "Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease," *Brain Res. Bull.*, vol. 87, no. 2–3, pp. 144–153, Feb. 2012.
- [11] M. Grundman, M. Grundman, and P. Delaney, "Antioxidant strategies for Alzheimer's disease," *Proc. Nutr. Soc.*, vol. 61, no. 2, pp. 191–202, May 2002.
- [12] M. Grundman, M. Grundman, and P. Delaney, "Antioxidant strategies for Alzheimer's disease," *Proc. Nutr. Soc.*, vol. 61, no. 2, pp. 191–202, May 2002.
- [13] A. Klugman, D. P. Naughton, M. Isaac, I. Shah, A. Petroczi, and N. Tabet, "Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors," *J. Alzheimers Dis. JAD*, vol. 30, no. 3, pp. 467–474, 2012.
- [14] S. Umukoro, F. A. Adewole, A. T. Eduviere, A. O. Aderibigbe, and C. Onwuchekwa, "Free radical scavenging effect of donepezil as the possible contribution to its memory enhancing activity in mice," *Drug Res.*, vol. 64, no. 5, pp. 236–239, May 2014.
- [15] X.-Y. Meng, H.-X. Zhang, M. Mezei, and M. Cui, "Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery," *Curr. Comput. Aided-Drug Des.*, vol. 7, no. 2, pp. 146–157, Jun. 2011.
- [16] G. M. Morris *et al.*, "AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility," *J. Comput. Chem.*, vol. 30, no. 16, pp. 2785–2791, Dec. 2009.
- [17] P. R. N. Wolohan and R. D. Clark, "Predicting drug pharmacokinetic properties using molecular interaction fields and SIMCA," *J. Comput. Aided Mol. Des.*, vol. 17, no. 1, pp. 65–76, Jan. 2003.
- [18] G. Moroy, V. Y. Martiny, P. Vayer, B. O. Villoutreix, and M. A. Miteva, "Toward in silico structure-based ADMET prediction in drug discovery," *Drug Discov. Today*, vol. 17, no. 1–2, pp. 44–55, Jan. 2012.
- [19] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings," *Adv. Drug Deliv. Rev.*, vol. 46, no. 1–3, pp. 3–26, Mar. 2001.
- [20] M. N. Drwal, P. Banerjee, M. Dunkel, M. R. Wettig, and R. Preissner, "ProTox: a web server for the in silico prediction of rodent oral toxicity," *Nucleic Acids Res.*, vol. 42, no. W1, pp. W53–W58, Jul. 2014.
- [21] M. U. Johansson, V. Zoete, O. Michielin, and N. Guex, "Defining and searching for structural motifs using DeepView/Swiss-PdbViewer," *BMC Bioinformatics*, vol. 13, no. 1, p. 173, 2012.
- [22] G. M. Morris *et al.*, "AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility," *J. Comput. Chem.*, vol. 30, no. 16, pp. 2785–2791, Dec. 2009.
- [23] D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward, and K. D. Kopple, "Molecular properties that influence the oral bioavailability of drug candidates," *J. Med. Chem.*, vol. 45, no. 12, pp. 2615–2623, Jun. 2002.

- [24] D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward, and K. D. Kopple, "Molecular Properties That Influence the Oral Bioavailability of Drug Candidates," *J. Med. Chem.*, vol. 45, no. 12, pp. 2615–2623, Jun. 2002.
- [25] Y. H. Zhao *et al.*, "Rate-limited steps of human oral absorption and QSAR studies," *Pharm. Res.*, vol. 19, no. 10, pp. 1446–1457, Oct. 2002.
- [26] B. S. Selinsky, K. Gupta, C. T. Sharkey, and P. J. Loll, "Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations," *Biochemistry (Mosc.)*, vol. 40, no. 17, pp. 5172–5180, May 2001.
- [27] S. Bencharit *et al.*, "Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition," *Chem. Biol.*, vol. 10, no. 4, pp. 341–349, Apr. 2003.
- [28] H. Furukawa and E. Gouaux, "Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core," *EMBO J.*, vol. 22, no. 12, pp. 2873–2885, Jun. 2003.
- [29] R. Bhat *et al.*, "Structural Insights and Biological Effects of Glycogen Synthase Kinase 3-specific Inhibitor AR-A014418," *J. Biol. Chem.*, vol. 278, no. 46, pp. 45937–45945, Nov. 2003.
- [30] R. Fedorov, E. Hartmann, D. K. Ghosh, and I. Schlichting, "Structural Basis for the Specificity of the Nitric-oxide Synthase Inhibitors W1400 and N-Propyl-L-Arg for the Inducible and Neuronal Isoforms," *J. Biol. Chem.*, vol. 278, no. 46, pp. 45818–45825, Nov. 2003.
- [31] B.-J. Sung *et al.*, "Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules," *Nature*, vol. 425, no. 6953, pp. 98–102, Sep. 2003.
- [32] X. Niu *et al.*, "IK682, a tight binding inhibitor of TACE," *Arch. Biochem. Biophys.*, vol. 451, no. 1, pp. 43–50, Jul. 2006.
- [33] J. M. Watermeyer, W. L. Kröger, H. G. O'Neill, B. T. Sewell, and E. D. Sturrock, "Probing the basis of domain-dependent inhibition using novel ketone inhibitors of Angiotensin-converting enzyme," *Biochemistry (Mosc.)*, vol. 47, no. 22, pp. 5942–5950, Jun. 2008.
- [34] J. Cao *et al.*, "Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors," *Bioorg. Med. Chem. Lett.*, vol. 19, no. 10, pp. 2891–2895, May 2009.
- [35] A. J. Vecchio and M. G. Malkowski, "The structure of NS-398 bound to cyclooxygenase-2," *J. Struct. Biol.*, vol. 176, no. 2, pp. 254–258, Nov. 2011.
- [36] M. Wandhammer *et al.*, "A step toward the reactivation of aged cholinesterases--crystal structure of ligands binding to aged human butyrylcholinesterase," *Chem. Biol. Interact.*, vol. 203, no. 1, pp. 19–23, Mar. 2013.
- [37] J. N. Cumming *et al.*, "Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor," *Bioorg. Med. Chem. Lett.*, vol. 22, no. 7, pp. 2444–2449, Apr. 2012.
- [38] J. Cheung *et al.*, "Structures of human acetylcholinesterase in complex with pharmacologically important ligands," *J. Med. Chem.*, vol. 55, no. 22, pp. 10282–10286, Nov. 2012.
- [39] N. Ansari and F. Khodaghali, "Natural Products as Promising Drug Candidates for the Treatment of Alzheimer's Disease: Molecular Mechanism Aspect," *Curr. Neuropharmacol.*, vol. 11, no. 4, pp. 414–429, Jun. 2013.
- [40] D. J. Newman and G. M. Cragg, "Natural products as sources of new drugs over the 30 years from 1981 to 2010," *J. Nat. Prod.*, vol. 75, no. 3, pp. 311–335, Mar. 2012.
- [41] A. Badrul and Haque Ekramu, "Anti-Alzheimer and Antioxidant Activity of *Celastrus paniculatus* Seed," *Iran. J. Pharm. Sci.*, vol. 7, no. 1, p. 49–56.

Figure-1




Figure-2




Figure-3




Figure-4




Figure-5

